Dubai, UAE – January 12, 2026 — Kings Research today announced the release of its latest market intelligence study, “Global AI in Medical Diagnostics Market: Size, Share, Trends & Forecast 2025–2032.” The report provides a comprehensive analysis of the market’s trajectory, including forecasts, drivers, opportunities, and competitive dynamics.
According to Kings Research, the global AI in Medical Diagnostics market was valued at USD 1,467.8 million in 2024 and is projected to grow from USD 1,749.2 million in 2025 to USD 7,083.7 million by 2032, at a CAGR of 22.12% during 2025–2032. Hospitals, diagnostic centers, and imaging facilities are increasingly adopting AI-driven diagnostic solutions to improve accuracy, reduce turnaround times, and enhance patient outcomes. This growing adoption is reflected in regulatory activity, as the U.S. Food and Drug Administration (FDA) had authorized, cleared, or approved approximately 950 AI- and machine learning–enabled medical devices as of August 2024, with a significant concentration in diagnostic applications (Source: www.congress.gov).
AI in medical diagnostics leverages machine learning, computer vision, natural language processing, and predictive analytics to assist healthcare professionals in disease detection, imaging analysis, and clinical decision-making. Notably, around 76% of FDA-authorized AI/ML medical devices are used in radiology, underscoring the technology’s central role in medical imaging and diagnostic interpretation. By combining advanced algorithms with medical imaging and patient data, these technologies help reduce diagnostic errors, optimize workflows, and accelerate personalized treatment strategies.
Kings Research identifies the following growth accelerators:
1. AI-Enhanced Imaging Solutions:
Hospitals and clinics are deploying AI-powered imaging tools to improve early disease detection, reduce manual workload, and standardize interpretation of radiology scans. Peer-reviewed studies indexed by the U.S. National Institutes of Health report that several FDA-approved AI diagnostic systems in imaging demonstrate expert-level clinical performance, achieving area-under-the-curve (AUC) values as high as 0.94 in cancer detection and related diagnostic tasks.
2. Clinical Decision Support Integration:
AI platforms integrated into diagnostic workflows increasingly support physicians with predictive analytics and real-time insights. The FDA and U.S. Congress have highlighted the expanding use of AI-enabled decision-support tools as part of regulated medical devices, reflecting growing confidence in data-driven clinical assistance.
3. Workflow Optimization:
Diagnostic centers are leveraging AI for automated triaging, report generation, and error reduction. According to FDA publications, federal regulators are actively monitoring real-world performance of AI-enabled diagnostic devices, acknowledging their expanding role in improving efficiency and consistency across clinical workflows (Source: www.fda.gov).
4. Innovation in Diagnostics:
Ongoing innovation continues to shape the diagnostic landscape, with new AI-based imaging and tumor-detection tools entering regulated clinical use. Reviews of FDA-authorized devices published through NIH-hosted journals confirm a steady increase in approved diagnostic AI technologies since 2016, highlighting sustained technological evolution within regulated healthcare environments (Source: pmc.ncbi.nlm.nih.gov).
5. Regional Expansion:
North America remains a leading region for AI-enabled diagnostics, supported by early technology adoption, strong healthcare infrastructure, and active FDA oversight of AI/ML medical devices. Meanwhile, Asia-Pacific is emerging as a high-growth region, driven by expanding diagnostic services and increased integration of AI technologies into healthcare systems.
For decision makers—CIOs, CTOs, COOs, and hospital administrators—the AI in medical diagnostics market presents compelling opportunities:
- Accuracy & Efficiency: Improved diagnostic precision reduces errors and accelerates patient care.
- Cost Optimization: Automation and AI reduce manual labor and diagnostic turnaround times.
- Scalability & Agility: Cloud-enabled and AI-integrated solutions support rapid deployment across multiple facilities.
- Compliance & Risk Mitigation: Built-in auditability improves adherence to regulatory standards.
- Innovation & Experience: Advanced diagnostics enhance both patient satisfaction and clinical outcomes, offering competitive differentiation.
Regional Outlook
- North America: Largest share, supported by early adoption of AI solutions in hospitals and diagnostic imaging centers.
- Asia-Pacific: Fastest-growing region (2025–2032), driven by rising healthcare investments, industrial-scale diagnostic expansion, and adoption of innovative AI solutions.
Competitive Landscape
Prominent companies are expanding via acquisitions, partnerships, and product launches. Key market players include Aidoc, Olympus, Akoya Biosciences, Inc., Siemens Healthineers AG, Zebra Technologies Corp., Imagen, AliveCor, Inc., GE HealthCare, Cleerly, Inc., Heartflow, Inc., Ibex Medical Analytics, Nano-X Imaging Ltd, Lunit Inc., EchoNous Inc., and NVIDIA Corporation.
The full Kings Research report provides detailed segmentation by component, application, end user, region, and competitive benchmarking. To request a sample, access the full report, or explore custom consulting services, please visit https://www.kingsresearch.com/report/ai-in-medical-diagnostics-market-3011.
Kings Research is a global provider of syndicated research reports and consulting services, helping organizations navigate emerging markets, assess opportunities, and make informed business decisions.
All market data are sourced from Kings Research proprietary analysis, validated against public releases and credible industry sources. Examples cited include U.S. Food and Drug Administration (FDA), U.S. Congress, and U.S. National Institutes of Health (NIH).